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Following a national law introduced in 2017 in Thailand, the selection of win-
ning bidders for multisourced pharmaceuticals and medical supplies in public 
hospitals must reflect “price-performance” aligned with the principles of worthi-
ness, transparency, efficiency, effectiveness and accountability. We describe how a 
practical tool using Multiple Criteria Decision Analysis (MCDA) for evidence-based 
decision making in hospital bidding (tender) was developed through a multi-
stakeholder workshop format. The local leader of the initiative together with 2 
international advisors guided the 37 workshop participants through five interactive 
steps for local adaptation of the previously developed and validated global MCDA-
tool: (1) Criteria selection, (2) Scoring definition, (3) Weighting of price criterion, 
(4) Definition of cut-off point for price criterion, (5) Ranking and weighting of 
remaining criteria. All consensus judgments were imported to the decision tool 
which can later be used in the real-world situation in the hospitals to support the 
selection and document the underlying rationale. The final list of criteria differs 
from the previously suggested international template and now reflects the Thai 
decision priorities and current decision processes. In the book chapter, the resulting 
model will be presented and a pathway for implementation will be discussed.
Keywords: multiple-criteria decision analysis, MCDA, Thailand, multisource 
pharmaceuticals, hospital tender, hospital bidding, performance
1. Introduction
Pharmaceutical procurement in Thailand has a long history of deconcentration of 
procurement management and decisions to the Provincial Health Office (PHO) and 
all public hospitals. This includes the delegation of power to generate, retain, and 
use financial revenues according to regulations and subject to regular audits by the 
auditor general [1]. Thus, purchasing for hospital pharmaceuticals is strongly decen-
tralized. Before the deployment of the Public Procurement Act BE 2560 (AD 2017) 
in 2017, the single selection criterion in the tender or bidding, as called in Thailand, 
was the lowest price. Since the establishment of Public Procurement Act, the bidder 
selection for multisourced supplies, including pharmaceutical and medical products, 
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has been expanded beyond “price” to “price-performance” in order to align with 
the principles of the Act concerning worthiness, transparency, efficiency, effective-
ness, and accountability. While public hospitals are encouraged to use performance 
criteria to determine the suppliers for pharmaceutical products, there is still a lack 
of a standard definition of what these criteria encompass and how important each 
of them is in making the decision. This may lead to a high level of variation between 
the hospitals on the formulary composition and in the methods used to shape the 
specific bidding process. To increase the overall quality and transparency based on 
the Public Procurement Act BE 2560 (AD 2017), the government is now requiring a 
solid rational and transparent documentation of hospital purchasing decisions.
Multiple-criteria decision analysis (MCDA) is a method which has been sug-
gested as a tool for the evidence-based assessment of multisource pharmaceuticals 
in developing countries [2]. MCDA can help to consider multiple and sometimes 
conflicting criteria in the evaluation of the available alternatives [3].
By considering multiple criteria, individuals or groups can follow an explicit 
structure for arriving at a decision that best fulfills the criteria [4]. In 2016, a task 
force of the International Society for Pharmacoeconomics and Outcomes Research 
(www.ispor.org) set out to give guidance for the best practices of MCDA in healthcare 
decision-making [5, 6]. In this, the development and use of MCDA are described as 
an iterative process containing several elements, which may be adapted to the specific 
use by the key stakeholders involved in the decision. At the start, it is important to 
define the decision problem with the objective, the stakeholders, the expected alter-
natives, and the expected output. Based on this, criteria for evaluation can be deter-
mined which reflect the important attributes or drivers for the success in the decision. 
For each of the criteria, a scoring scale or graduation needs to be determined. If the 
criteria (or attributes) have a different importance in reaching the overall objective, 
the criteria will have to be weighted according to their importance [5, 6].
In the actual evaluation of the alternatives, the performance in each criterion is 
scored separately for the available alternatives and contributes with the predeter-
mined weight, according to its relative importance, to the composite score reflect-
ing the overall performance of the alternative.1 When comparing alternatives, the 
MCDA will result in a “score profile” for each alternative and a composite score, 
which is generated by the MCDA model. The result is not the decision but structured 
information to better inform the decision to be made. MCDA is being used widely 
to inform decision-making in healthcare, including benefit-risk assessment of 
medicine, formulary listing, or reimbursement decisions [5, 7]. Examples for using 
MCDA in decision-making for multisource medicines in developing countries are 
emerging in several countries such as China, Thailand, or Egypt [8, 9]. MCDA could 
be a solution for hospitals in Thailand to select those products which best meet the 
needs of the patients, providers, and the national policy makers for healthcare.
Thailand has a strong history of using multiple-criteria decision analysis 
(MCDA), considering the value of pharmaceuticals as an important component in 
pharmaceutical policy planning, price negotiation, development of clinical practice 
guidelines, and communication with health professionals [10, 11]. It has been rec-
ognized that MCDA enhances the legitimacy of policy decisions by increasing the 
transparency, systematic nature, and inclusiveness of the process [10]. Examples 
for using the MCDA method on a national level for rational, transparent, and fair 
priority setting in the context of single-source drugs have been described [12].
The objective of this initiative was to develop a simple tool for improving 
decision-making in the hospital bidding setting, based on the MCDA methodology, 
1A short explanation of MCDA in lay language (English) can be seen under https://www.youtube.com/
watch?v=7OoKJHvsUbo.
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through a multi-stakeholder workshop format to attain consensus. This tool should 
integrate a set of standard decision criteria, which (1) can be used by hospital 
purchasers to base bidding decisions on both performance and price, (2) would be 
applicable across diverse hospitals and institutions, but (3) would also allow for 
adaptation to local priorities.
2. Methods
On June 29, 2018, key stakeholders and experts in pharmaceutical bidding 
policies in Thailand came together on invitation by the Pharmaceutical Association 
of Thailand under Royal Patronage (PAT). The 37 active workshop participants rep-
resented multiple perspectives in Thailand (24 pharmaceutical purchasing (12 of 
these from leading hospitals), 7 academic pharmacy education leaders, 4 from the 
Ministry of Health, 1 from PAT, and 1 from an industry association) in addition to 
2 observers from the regulatory perspective. During the 1-day workshop, all active 
participants were involved in developing an MCDA tool which can be used in mak-
ing decisions in the hospital bidding setting.
Two international health policy advisors moderated the workshop following a 
validated MCDA calculation model and process for local adaptation [13]. Together 
with the local leader of the initiative, the international experts used a structured 
process as described in Figure 1 to prepare the workshop, align the participants’ 
expectations and knowledge at the workshop, and to guide the workshop partici-
pants through five steps for the local adaptation of the MCDA format. The interna-
tional advisors conducted the workshop in English language. However, to ensure 
that all participants could follow the discussions and freely express their experi-
ences and opinions at all times, independent of their knowledge of either Thai or 
English, the workshop was supported by a two-way simultaneous translation.
The workshop started by defining all non-price criteria which may be 
relevant in the Thai decision process. These were defined starting from the 
Figure 1. 
Description of the entire process for developing a value-based decision tool for multisource pharmaceutical 
bidding in Thai hospitals.
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basic decision criteria proposed by international health policy thought leaders 
[2] and an adapted set of these criteria which had gone through a preliminary 
adaptation to current Thai decision priorities before the workshop, by the local 
leadership team of the initiative (Step 1). This involved a detailed moderated 
discussion of each of the criteria and of the measures used for scoring each of 
the criteria (Step 2).
Subsequently, the participants determined the weight of the price criterion (Step 3) 
in the overall decision and the acceptable price range and cutoff point qualifying a 
product for positive ratings on the price criterion (Step 4). After this, the relative 
importance of each of the criteria in the overall decision was determined following the 
modified simple multi-attribute rating technique (SMART) method [9] for ranking 
and swing weighting of the criteria (Step 5). Steps 3–5 included anonymous vot-
ing by the participants using an audience response system (Ombea® with OMBEA 
ResponsePad™). The results of each voting were shown directly to the audience. In 
case of large variations or disagreements between the voters, the arguments of the 
participants in support of their votes were deliberated in open discussion followed by a 
second voting. For the voting on price and the cutoff point, the result was computed by 
assessing the median value. For the ranking of the criteria, the majority vote was used 
in repeated voting rounds to select the most important of the remaining criteria.
An important step after the workshop will be the testing and validation of the 
tool in a realistic setting (piloting) with monitoring of the results, the revision 
based on the learnings during the pilot, and, finally, the full implementation as 
summarized in the right part of Figure 1.
3. Results of the workshop
The discussion among the participants confirmed that currently there is no 
uniform evaluation method applied to bidding decision-making in hospitals 
and that there is a need for more consistency and better decision documentation 
on one side but also a need to adapt the weighting or criteria to local situations 
in cases where there are special environmental conditions. In addition, there 
was a general agreement that the decision should not solely be based on price, 
because major differences relating to quality and reliability or other factors with 
the healthcare impact are observed in real life between the products offered by 
different suppliers in Thailand. The advantages of using a consistent approach 
involving the MCDA methodology would be, on the one hand, the improved 
decision consistency and equity and, on the other hand, the high transparency 
and documentation of decisions versus all stakeholders with interest in the 
decision (e.g., manufacturers, government agencies, quality control, hospital 
administration, and providers).
3.1 Pre-workshop preparation
Based on experience with the local legal-structural setting, desk research, and a 
pre-workshop survey among the workshop participants, the leadership team (Thai 
academic pharmacy experts with international advisors) described 11 relevant 
criteria, including:
• Six product quality criteria, equivalence with the reference (original) product, 
stability and drug formulation, product quality determined by the Certificates 
of Analysis (CoA) of both the finished product and the active pharmaceutical 
ingredient (API), and the product specifications of both the finished product 
and the API
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• Three criteria relating to the manufacturer quality, the manufacturing stan-
dard of both the finished product and the API, as well as the reliability of drug 
supply, pharmacovigilance, and added value service related to the product.
3.2 Workshop
3.2.1 Step 1: selection of non-price criteria
At the beginning of the interactive part of the workshop, the participants discussed 
and selected the most important non-price criteria which should be considered for 
determining the value of multisource pharmaceuticals starting from the set of criteria 
resulting from the pre-workshop preparation. During this discussion, several altera-
tions were adopted so that it finally resulted in 10 non-price selection criteria, of which:
Criterion name Scoring (possible outcomes) Score
Equivalence with the 
reference (original) 
product
No data on pharmaceutical equivalence 0%
Pharmaceutical equivalence 10%
Bioequivalence proven in compliance with the Thai FDA 30%
Bioequivalence approved by the Thai FDA and with the European 
EMA or US FDA standard
70%
Bioequivalence approved by the Thai FDA and with the European 
EMA or US FDA approval
80%
Therapeutic efficacy or equivalence proven in a clinical trial 100%
Stability and drug 
formulation
No data on product expiry or stability EXCL
Have data (1) long-term study (full shelf life), but do not follow the 
ASEAN guidelines
10%
Have data (1) long-term study (full shelf life) and follow the ASEAN 
guidelines
50%
Have data (1) and (3) latest yearlong-term stability study or (4) 
in-use stability data for the drug which needed to be mixed before 
use (drug to be mixed before use must have “in-use stability data”) 
but do not follow the ASEAN guidelines or have only data (1) which 
follow the ASEAN guidelines
75%






Limited information on quality assurance EXCL
Country of origin GMP quality assurance 33%
WHO GMP certification 67%
EU or PIC/S GMP 100%
Quality: certificate of 
analysis (CoA) finished 
product
Not comply with registered finished product specification EXCL
Partially comply with registered finished product specification EXCL




Do not comply with registered specification EXCL
Follow the previous pharmacopeia version or in-house specification 
with topics not aligned with the general chapters
50%




List of criteria with consensus scoring (qualitative descriptive) (Part 1).
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Criterion name Scoring (possible outcomes) Score
Quality: manufacturing 
standard API
Limited information on quality assurance EXCL
Country of origin GMP quality assurance 33%
WHO GMP certification 67%
EU or PIC/S GMP 100%
Quality: product specification 
API
Not comply with registered specification EXCL
Follow the previous pharmacopeia version or in-house 
specification with topics not aligned with the general chapters
50%
Follow updated pharmacopeia or in-house specification with 
topics recommended by pharmacopeia
100%
Added value service on the 
hospital level
No program or service 0%
Low value (meets one criterion) 33%
Moderate value (meets two criteria) 66%
High value (meets three criteria) 100%
Macroeconomic benefit The manufacturer has no local investment in the country 0%
The manufacturer has minor local investment in the country 33%
The manufacturer has moderate local investment in the 
country
67%
The manufacturer has significant local investment in the 
country
100%
Reliability of drug supply Major and multiple problems in the last 2 years 0%
Minor and occasional problems in the last 2 years 20%
Single precedence of supply problems in the last 2 years 50%
No precedent of supply problems in the last 2 years 80%




List of criteria with consensus scoring (qualitative descriptive) (Part 2).
• Five relate specifically to the product (equivalence with the reference (original) 
product, stability, and drug formulation, the product quality determined by 
the CoA of the finished product, and the product specifications of both the 
finished product and the API).
• Three relate to the manufacturer (the manufacturing standard of both the 
finished product and the API as well as the reliability of drug supply).
• Two relate to additional value beyond the actual product (added value services 
at the hospital level and macroeconomic benefit in terms of local investments 
by the manufacturer).
Two other criteria have been considered but were not adopted to the final essen-
tial list of decision criteria: The Certificate of Analysis for the API was considered a 
prerequisite to enter the bidding and, therefore, would not be relevant for further 
differentiation between the products; pharmacovigilance was also not considered 
relevant for the multisource pharmaceuticals used in the hospital setting. In addi-
tion, it was warned that this criterion might introduce an unfair bias toward the 
originator products who are usually the only ones pursuing a pharmacovigilance 
database on the national or international level.
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3.2.2 Step 2: criteria scoring
For all selected criteria, the measurement scales were discussed in some cases; 
the previously suggested rating were adapted by the participants as considered 
more appropriate in the Thai hospital setting. The detailed descriptions of the 
criteria scoring are listed in Tables 1 and 2.
3.2.3 Step 3: weight of price criterion
Subsequently, the relative importance of the price criterion was determined 
by voting and was determined to be 40% of the overall decision, which is already 
established as a general ratio for chemical pharmaceutical products.
Figure 2. 
Graphic representation of the scoring for the procurement price difference in comparison to the lowest price 
product. The cutoff point determined in the workshop was an excess price of 100%. All prices higher than this 
cutoff point receive a score of 0%.




Price Quantitative 1 40
Equivalence with the reference 
(original) product
Qualitative 2 12.2
Product quality: certificate of analysis 
(CoA) finished product
Yes/no (no = exclusion) 3 8.7
Manufacturer quality: manufacturing 
standard finished product
Qualitative 4 8.7
Stability and drug formulation Qualitative 5 7.3
Product quality: product specification 
(finished product)
Qualitative 6 5.8
Quality: product specification API Qualitative 7 4.9
Quality: manufacturing standard API Qualitative 8 4.0
Added value service on the hospital level Qualitative 9 3.1
Reliability of drug supply Qualitative 10 2.8
Macroeconomic benefit Qualitative 11 2.5
Table 3. 
Results of the consensus workshop for the relative importance of the evaluation criteria and their weight in the 
final score for each option.
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Figure 3. 
Impact of each decision criterion in the evaluation on the final decision (top axis: impact percentage). 
Abbreviations: CoA = certificate of analysis, Std. = standard, API = active pharmaceutical ingredient.
3.2.4 Step 4: scoring of price criterion
To enable a quantitative scoring function for the price criterion, the participants 
had to determine the cutoff point for the price. This median cutoff point was voted 
to be an excess price of 100% based on the acceptance threshold defined by the 
current guideline of Comptroller General’s Department. As shown in Figure 2, this 
means that all products with prices which are 100% or higher than the lowest price 
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offered in the bidding would receive a score of zero for the pricing criterion in the 
evaluation.
3.2.5  Step 5: ranking and weighting of non-price criteria by “SMART and swing” 
method
Finally, the selected criteria were ranked and rated for their weight in the 
final decision round [7]. The results are summarized in Table 3 in the column 
“Final weights.” The impact of each criterion on the final decision is shown in 
Figure 3.
3.3 Workshop follow-up
Finally, all participants agreed that the resulting model seemed appropriate to 
be used for selecting bidding winners in Thai hospitals and that it should be tested 
in real-life pilot applications. Hence, after the MCDA model has in this workshop 
been adapted to the Thai hospital decision context by Thai stakeholders from a 
broad range of healthcare-related institutions, two additional steps are important 
to ensure applicability in the hospital setting: (1) piloting and validating in real-life 
decision processes and (2) refinement based on the experiences in the piloting in 
selected hospitals. Realizing such a pilot application will require involvement of all 
functions concerned in the specific hospital decision process and their agreement. 
This will be facilitated through support from the local leader of the initiative.
4. Discussion
In this report we have described a structured process to adapt the template of 
a validated international multiple-criteria scoring decision format to the specific 
setting of making performance-based decisions for public purchasing in Thai 
hospitals. The involvement of a broad stakeholder group in the design process is 
critical for the acceptance and subsequent implementation of the methodology. In 
this workshop, there were 37 participants who represented the user perspectives as 
well as the administrative or regulatory perspectives, the academic expertise and 
the perspectives of the pharmacist profession through PAT and of the industry by 
representation of the Pharmaceutical Research and Manufacturers Association 
(PReMA, http://www.prema.or.th).
Although using a standardized process for the workshop and a previously 
designed Excel-based model template [13], the participants were involved in 
each step of designing the specific Thai decision tool during a 1-day workshop. 
Continuing the participatory process by involving the important purchasing stake-
holders in the pilots and the evaluation will further foster full transparency and 
improvement through user feedback, and, finally, it should support endorsement of 
the process in the specific Thai hospital bidding decision context. The participants 
agreed to the approach and considered the resulting MCDA tool to be suitable to 
improve the transparency and consistency of decision-making for multisource 
pharmaceuticals in Thai hospitals.
The MCDA model is a living instrument which can be revised when the priori-
ties and needs in the healthcare system and policies change. Therefore, criteria 
can be included, excluded, or adapted at a later stage once a new consensus on the 
importance and the transparent measures for qualification is reached among the 
users of the instrument due to new developments and experiences. For example, 
it has been proposed by some participants that some flexibility might be advisable 
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for the weighting of the price criterion when evaluating a specific type of product 
such as lifesaving medicines or a stricter scoring of the quality criteria when it 
comes to narrow therapeutic window drugs. An adaptation of the price weight 
depending on such considerations is possible on the hospital level if required. 
Another point for reconsideration after testing the tool in the real-life situation 
resulted from the discussion of the criterion of the “Certificate of Analysis for the 
finished product”: in the final model, the scoring was determined as either com-
plying with the specifications (=100%) or not complying (exclusion). Thus, this 
criterion may be considered as another prerequisite to enter the bidding instead of 
a MCDA decision criterion.
The final list of criteria selected in this initial workshop for the resulting MCDA 
model shows some deviations from the criteria which were previously suggested by 
an international expert group [2] and which were selected in other countries which 
adapted the tool to their settings [13]. This reflects the active engagement and 
contribution of the participants who critically questioned and deliberated each of 
the proposed criteria in comparison to their current decision processes.
After successful piloting, evaluation, and refinement of the model based on 
the real-life experience, a roadmap for further dissemination and implementation 
should be developed.
The process presented here for the adaption of a multiple-criteria scoring format 
to the specific decision problem in Thailand follows the general process as suggested 
by the ISPOR task force [5, 6]. The core elements in this process were addressed 
with a group of Thai stakeholders in the hospital purchasing processes, who repre-
sented a range of hospitals.
While the selection of criteria, the ranking, and the weighting require adapta-
tion to the specific decision problem and policy framework, the process itself can 
be generalized and transferred to other countries or organizations. The foundation 
for the course of work steps in preparation of the workshop, conduct of the work-
shop, and follow-up has been formed through the experience from three countries, 
Indonesia, Kazakhstan, and Vietnam [13, 14]. In each of these countries, different 
types of purchasing or tender decision problems (national purchasing, public 
tender) had been addressed. In this book, another example is presented, where the 
process was followed to develop a decision analysis tool to help provincial policy 
makers with the comparison of alternative insurance policies in China [15]. For 
that, a new set of decision criteria had to be compiled, which reflected the needs to 
be addressed by a policy change from the stakeholder perspective. However, despite 
that the objective to select the optimal future insurance policy is very different 
from the objective which guided the Thai initiative, the same process was followed 
in China: preparation with desk research and discussions with local stakeholders, 
workshop with consensus on the purpose of the tool, selection of the criteria, 
prioritization and ranking of the criteria, and follow-up with testing and piloting. 
The most important element is the engagement with and of those stakeholders 
who are concerned by the decision. How each of the procedural elements is shaped 
in the specific local application will strongly depend on the local preferences and 
needs. If the participating stakeholders are already familiar with the principles of 
MCDA, such as in Thailand, a 1-day workshop format may suffice. In Indonesia 
and Kazakhstan, a 2-day format was preferred which allowed for more presentation 
of the technical and methodological information before entering the interactive 
workshop parts. In all cases, we saw that the discussion at each step throughout the 
workshop is essential for building consensus.
Another important consideration should be that the current values and daily 
routines are considered when selecting the criteria. For example, the original 
list of internationally validated criteria was modulated in Thailand to satisfy the 
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traditionally high use of specific quality measures. If the MCDA process shall be 
used for tender decisions, it will be important to train the users who may previ-
ously only have used the price or a very limited amount of information to select the 
winning bid. A standard template for dossier submission may facilitate the targeted 
supply of data and information for the manufacturers, a standard template for data 
as has been proposed by Brixner et al. in consequence of the experiences in the pre-
vious workshops [16]. Increasing experience with the implementation for further 
applications in CEHCs and ongoing evaluation and communication will help in the 
efficient implementation of new initiatives.
A limitation of the approach presented here for developing a MCDA tool to be 
used for hospital purchasing may be that the initial design is limited to the num-
ber of participants and the breadth of stakeholder groups involved in the design 
workshop. However, further involvement will be achieved throughout the pilot-
ing through communication of the experiences after each step of the process and 
through updating of the tool based on the practical experience.
5. Conclusions
The present paper describes how MCDA can be easily adapted to different 
countries and decision-making settings to improve the efficiency and transparency 
of the decision-making process, in the case of the undertaking of pharmaceutical 
bidding. The approach described here can be easily adapted to other countries and 
decision-making settings.
A short explanation of the principles of multiple-criteria decision analysis and 
the use in decisions on pharmaceuticals can be viewed at https://www.youtube.com/
watch?v=7OoKJHvsUbo.
Conflict of interest
The research underlying this methodology was partially financed by 
Abbott Products Operations AG, Switzerland. The workshop was hosted by the 
Pharmaceutical Association of Thailand under Royal Patronage (PAT) who received 
funding by an unrestrictive educational grant. The international facilitation and the 
open-access publication fee were also financed by Abbott Products Operations AG, 
Switzerland.
Notes/thanks/other declarations
All workshop participants have actively contributed to the results of the 
workshop. We would specially thank the following participants, who have sup-
ported us during the preparation and the workshop and in the writing of this 
manuscript:
Ms. Jutatip Meepadung, Buddhachinaraj Hospital, Buddhachinaraj Hospital 90 
Srithammaratipitak Road Amphoe Mueang Phitsanulok, Chang Wat Phitsanulok 
65000.
Ms. Warawan Chungsivapornpong, Veterans General Hospital, Veterans General 
Hospital 123 Vibhavadi Rangsit Road, Samsennai Phayathai Bangkok 10400.
Mrs. Patcharin Suvanakoot, Ramathibodi Hospital, Bangkok.
Mrs. Montakarn Rahong; Bhumibol Adulyadej Hospital, Khlong Toei.
Mrs. Kannika Pongthranggoon, Thammasat University Hospital, Khlong Luang.
Evaluation of Health Services
12
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Author details
Anunchai Assawamakin1, Anke-Peggy Holtorf2* and Nikolaos Maniadakis3
1 Department of Pharmacology, Faculty of Pharmacy, Mahidol University, 
Bangkok, Thailand
2 Health Outcomes Strategies GmbH, Basel, Switzerland
3 National School of Public Health, Greece
*Address all correspondence to: anke.holtorf@health-os.com
Dr. Suriyan Thengyai, School of Pharmacy, Walailak University, 
Nakhonsithammarat.
Mr. Thurdsak Piriyakakul, Ratchaburi Hospital, Ratchaburi.
Assoc. Prof. Payom Wongpoowarak, Faculty of Pharmacy, PSU (Prince of 
Songkla University), Songkhla.
Mr. Hatairat Panparipat, Rayong Hospital, Rayong.
Mr. Thanapoom Kiewchaum, Faculty of Pharmacy Chiang Mai University, 
Chiang Mai.
Mrs. Patcharawan Meesilp, Faculty of Pharmacy Chiang Mai University, 
Chiang Mai.
Mrs. Surirat Tangsangasaksri, Hatyai Hospital; Songkhla.
13
Weighing Price and Performance for Decisions for Multisource Pharmaceutical Bidding in Public…
DOI: http://dx.doi.org/10.5772/intechopen.83823
References
[1] Jongudomsuk P, Srithamrongsawat 
S, Patcharanarumol W, 
Limwattananon S, Pannarunothai 
S, Vapatanavong P. The Kingdom 
of Thailand health system review. 
Manila, Philippines: World Health 
Organization, Regional Office for the 
Western Pacific; 2015. Available from: 
http://www.searo.who.int/entity/
asia_pacific_observatory/publications/
hits/hit_thailand/en/ [Accessed:  
23 July 2018]
[2] Brixner D, Maniadakis N, Kaló Z, 
Hu S, Shen J, Wijaya K. Considering 
multicriteria decision analysis (MCDA) 
simple scoring as an evidence-based 
HTA methodology for evaluating 
off-patent pharmaceuticals (OPPs) 
in emerging markets. Value in Health 
Regional Issues. 2017;13c:1-6. DOI: 
10.1016/j.vhri.2017.02.001
[3] Keeney RL, Raiffa H. Decisions with 
Multiple Objectives: Preferences and 
Value Trade-Offs. United Kingdom: 
Cambridge University Press; 1993. ISBN-
10: 0521438837, ISBN-13: 978-0521438834
[4] Belton V, Stewart T. Multiple Criteria 
Decision Analysis: An Integrated 
Approach. Springer US: Springer 
Science & Business Media, Kluwer 
Academic; 2002. ISBN-10: 079237505X, 
ISBN-13: 978-0792375050
[5] Thokala P, Devlin N, Marsh K, 
Baltussen R, Boysen M, Kalo Z, et al. 
Multiple criteria decision analysis 
for health care decision making—An 
introduction: Report 1 of the ISPOR 
MCDA emerging good practices task 
force. Value in Health. 2016;19:1-13. 
DOI: 10.1016/j.jval.2015.12.003
[6] Marsh K, Ijzerman M, Thokala P, 
Baltussen R, Boysen M, Kalo Z, et al. 
Multiple criteria decision analysis 
for health care decision making—
Emerging good practices: Report 
2 of the ISPOR MCDA emerging 
good practices task force. Value in 
Health. 2016;19:1-13. DOI: 10.1016/j.
jval.2015.12.003
[7] Communities and Local 
Government. Multi-criteria analysis: 
A manual. Wetherby, Great Britain: 
Department for Communities and 
Local Government; 2009. Available 
from: http://www.communities.gov.uk/
documents/corporate/pdf/1132618.pdf 
[Accessed: 24 March 2018]
[8] Hu S, Zhang Y, He J, Du L, Xu M,  
Xie C, et al. A case study of 
pharmaceutical pricing in China: 
Setting the price for off-patent 
originators. Applied Health Economics 
and Health Policy. 2015;13:13-20. DOI: 
10.1007/s40258-014-0150-5
[9] Tuan PL, Tuan Kiet PH, Brixner DI,  
Ngo VH. Development of Multiple 
Criteria Decision Analysis Framework 
for Off-patent Pharmaceuticals 
Decision Making in Vietnam | European 
Chamber of Commerce in Vietnam. 
Hanoi, Vietnam: European Chamber 
of Commerce Vietnam; 2017. Available 
from: https://www.eurochamvn.org/
node/16937 [Accessed: 23 March 2018]
[10] Youngkong S. Application of HTA 
research on policy decision-making. 
Journal of the Medical Association of 
Thailand. 2014;97(Suppl. 5):S119-S126
[11] Youngkong S, Teerawattananon Y, 
Tantivess S, Baltussen R. Multi-criteria 
decision analysis for setting priorities 
on HIV/AIDS interventions in Thailand. 
Health Research Policy and Systems. 
2012;10:6. DOI: 10.1186/1478-4505-10-6
[12] Youngkong S, Baltussen R,  
Tantivess S, Mohara A, 
Teerawattananon Y. Multicriteria 
decision analysis for including health 
interventions in the universal health 
coverage benefit package in Thailand. 
Value in Health. 2012;15:961-970
Evaluation of Health Services
14
[13] Inotai A, Brixner D, Maniadakis N, 
Dwiprahasto I, Kristin E, Prabowo A,  
et al. Development of multi-criteria 
analysis (MCDA) framework for off-
patent pharmaceuticals – an application 
on improving tender decision making 
in Indonesia. BMS Health Services 
Research. 2018;18. (online) https://doi.
org/10.1186%2Fs12913-018-3805-3
[14] Inotai A, Nguyen HT, Hidayat B, 
Nurgozhin T, Kiet PHT, Campbell JD,  
et al. Guidance towards the 
implementation of multi-criteria 
decision analysis framework in 
developing countries. Expert Review 
of Pharmacoeconomics and Outcomes 
Research. 2018;18:585-592. https://doi.
org/10.1080%2F14737167.2018.1508345
[15] Hu S, Holtorf AP, Wijaya K, He J,  
Brixner D. Value based evaluation for 
health insurance policy schemes in 
China’s provinces. In: Evaluation of 
Health Programs. London, UK; 2019
[16] Brixner D, Maniadakis N, 
Kaló Z, Kim K, Wijaya K. An 
evidence framework for off-patent 
pharmaceutical review (EFOR) for 
health technology assessment in 
emerging markets. Value in Health 
Regional Issues. 2018;16c:9-13.  
Available from: http://www.
valuehealthregionalissues.com
